Author

Estelle Saland

Centre de Recherches en Cancérologie de ToulouseORCID 0000-0001-8521-3061Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

A’ishah Bakayoko· 1 shared Akmal SalimoviD· 1 shared Andrew Matthews· 1 shared Angelo D’AlessandroiD· 1 shared Ann DevineiD· 1 shared Brian KeithiD· 1 shared Bryan Manning· 1 shared Catherine Lai· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A’ishah Bakayoko

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologyLeukemiaPeer-reviewedJul 9, 2025

Chemoresistance of TP53 mutant AML requires the mevalonate byproduct, GGPP, for regulation of ROS and induction of a mitochondria stress response

Sarah J. Skuli, A’ishah Bakayoko, Marisa Kruidenier…·Martin P Carroll

This study identifies GGPP, a mevalonate pathway byproduct, as critical for chemoresistance in TP53mut AML through ROS regulation and mitochondria stress response, suggesting statin-based therapies could be effective.

12 citationstop 2%

humanbulk RNA-seq

𝕏 PostBluesky